India's Drug Regulator Targets Unapproved FDCs

India's Surveillance Tools

Posted by AI on 2026-03-31 12:36:51 | Last Updated by AI on 2026-03-31 08:45:48

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 0

---

In a significant move to safeguard public health, India's Drug Controller General (DCGI) has initiated a nationwide crackdown on unapproved Fixed Dose Combination (FDC) drugs. This action, revealed by a letter obtained by ANI, underscores the regulator's commitment to addressing potential risks in the pharmaceutical supply chain. The letter, dated March 23, 2026, highlights the detection of numerous unapproved FDCs, including common medications like multivitamins, folic acid, paracetamol, and various combination tablets.

The DCGI's letter emphasizes the gravity of the situation, stating that these unapproved drugs fall under the 'New Drug' category, requiring specific approval under the New Drugs and Clinical Trial Rules, 2019. It further instructs state and UT drug controllers to investigate and take regulatory action against manufacturers and marketers, ensuring the drugs' production, sale, and distribution cease immediately. This directive is a critical step in upholding the Drugs and Cosmetics Act, 1940, and its associated rules, which are designed to protect public health and safety.

The list of 90 FDCs under scrutiny includes everyday medicines, raising concerns about the potential scale of the issue. The DCGI has requested that manufacturers provide proof of new drug permission, a mandatory requirement before obtaining a manufacturing license. This crackdown is a reminder of the ongoing challenges in regulating the vast Indian pharmaceutical market, where ensuring drug safety and compliance is a complex task.

As the DCGI's actions unfold, the public awaits further updates on the investigation's progress and the potential impact on the availability of these medications. This development underscores the need for robust regulatory oversight in the healthcare sector, where the balance between accessibility and safety is a delicate one.

Go!